Assessment of the quality of blood progenitor cell (BPC) collections is based mainly on CD34 + cell enumeration by flow cytometry, or scoring of granulocyte-macrophage colony-forming cells (CFU-GM). A minimum cell dose for haemopoietic recovery can be defined by both assays; however, the CFU-GM assay can not be used for 'real-time' decisions, whereas CD34
Rapid haematological recovery follows the majority of autologous blood progenitor cell transplants (ABPCT), and the speed of recovery correlates with the dose of infused cells. 1 However, a proportion of patients fail to mobilise adequate numbers of haemopoietic progenitor and stem cells to ensure rapid and durable engraftment; this fact, as well as the widespread use of cell selection methods, necessitates stringent quality testing of blood progenitor cell (BPC) collections.
Granulocyte-macrophage colony-forming cells (CFU-GM) in BPC harvests correlate with time to granulocyte and platelet recovery. 2, 3 The time required for the CFU-GM assay precludes its use for immediate decisions. In many centres, CFU-GM assay has been superseded by CD34 + cell enumeration by flow cytometry. CD34 + cell counts correlate with the CFU-GM counts, as well as with the speed of haemopoietic recovery after APBCT, 4 and have the advantage of being scored in less than 2 h. Nevertheless, standardisation of CD34 cell enumeration has not yet been fully achieved. As a result, reported minimum thresholds of CD34 cells for APBCT vary between 0.5-5 × 10 6 /kg. 1, 5 In addition, both CFU-GM and CD34 assays require expensive equipment and considerable staff time and expertise.
In a situation where APBCT is increasingly used, often outside large cancer centres, it may not always be possible to have a CD34 cell count performed for 'real-time' decisions. This may be the case even in centres with adequate facilities, if such decisions are to be made out of standard working hours. It is therefore desirable to have a simple, rapid and reliable method of assessing BPC harvest quality. We report our experience on the use of morphologically identified blasts in BPC harvests as a surrogate marker of harvest haemopoietic progenitor content, and a predictor of haemopoietic recovery after APBCT.
Patients and methods
The correlation between CFU-GM and blasts in BPC harvests was analysed on 97 apheresis samples collected from 58 patients with haematological malignancies. Twenty-four patients also had CD34 cell counts performed on 36 harvests. Fifty-seven patients were evaluable for the analysis of haemopoietic recovery after APBCT: 22 (38.5%) with NHL, 15 (26.3%) HD, 11 (19.2%) multiple myeloma, five (8.8%) AML, two (3.5%) CML, and one (1.7%) each ALL and MDS.
BPC were mobilised with cyclophosphamide 1.5 g/m 2 + G-CSF 5 g/kg in 36/58 patients, other chemotherapy and G-CSF in 16/58, and G-CSF 10 g/kg in 6/58 patients.
Harvests were commenced at the time of rapid WBC recovery, or, more recently, when the blood CD34 + cell count exceeded 10/l. In case of mobilisation with G-CSF alone, harvests were done on days 5 and 6 regardless of WBC or CD34 blood counts. Aphereses were performed on COBE Spectra (COBE Laboratories, Lakewood, CO, USA) processing 2.5-3 total blood volumes per apheresis.
Cell counts from each harvest were done on a Coulter counter or, since 1996 on the Sysmex SE-9000 haematology analyzer. A 1/5 dilution was frequently used to ensure more accurate cell counting. A differential count was done on May Grünwald-Giemsa-stained films, counting 1000 cells. The cells scored as blasts ( Figure 1 ) were small (size between the lymphocyte and mature granulocyte), agranular, with a high N/C ratio and open chromatin with prominent nucleoli. The degree of cytoplasmic basophilia was variable, and some blasts had a prominent Golgi zone. The absolute blast count was calculated from their percentage and the total nucleated cell count of the harvest. The 'inter-assay' variability was assessed by scoring the blast percentage on films from 10 harvests by three of us (AM, AP and GJM), in a blinded fashion. The result is expressed as the median coefficient of variation (CV) of all samples.
The CFU-GM/BFU-E assay was performed on unseparated, washed harvest cells, plated at 10 5 cells/ml in 1% methylcellulose (MethoCell; Stem Cell Laboratories, Vancouver, Canada) with 30% FCS (Globepharm Ltd, Esher, UK), 10% BSA (Sigma Chemicals, Poole, UK), 100 ng/ml GM-CSF (Leucomax; Sandoz Pharma, Basel, Switzerland) and 2 U/ml erythropoietin (Eprex; Cilag Ltd, Beerse, Belgium). CFU-GM were scored on day 14 as aggregates of Ͼ50 cells; BFU-E were scored as two or more red cell clusters, or a single aggregate of Ͼ200 cells.
The CD34 + cell analysis was done using CD45 FITC (Clone 2D1) and CD34 PE (Clone 8g12) together with appropriate isotype-matched controls, followed by lysis using FACS lyse (all Becton Dickinson, Oxford, UK). The analysis was performed on a Coulter XL flow cytometer (Coulter Electronics, Luton, UK). 100 000 CD45
+ events were collected and analysed using the gating strategy proposed by Bender et al, 6 to include cells that were CD34 + , which also had a low side scatter value.
The statistical analysis was done using GraphPad Prism version 2 (GraphPad Software, San Diego, CA, USA).
Results
The percentage of blasts in BPC collections ranged from 0-4%, with a mean of 0.80 Ϯ 1.13 (x Ϯ s.d.). Assessment of the 'inter-assay' variability by three observers resulted in a median CV of 25%, with the range of 10.8-166%. There was a strong, highly significant linear correlation between the BPC blast counts and the CD34 + cells (r = 0.854, P Ͻ 0.0001), as well as between blasts and CFU-GM (r = 0.773, P Ͻ 0.0001) (Figures 2 and 3) .
The median time to a granulocyte count of Ͼ0.5 × 10 9 /l post ABPCT was 12 days (range 8-20 days). The median time to a platelet count of Ͼ20 × 10 9 /l was 13.5 days (range 7-180 days). There was a significant inverse correlation between the time to granulocyte recovery and the logarithm of the absolute blast count (Log (bc)): r = −0.562, P Ͻ 0.0001 ( Figure 4) ; the time to platelet recovery also showed a significant, though somewhat weaker, negative correlation with the Log (bc): r = −0.437, P = 0.0012. However, deletion of a single outlier improved the correlation to r = −0.547 and P Ͻ 0.0001 ( Figure 5 ).
Out of 57 evaluable patients, three failed to engraft, and another 10 had delayed platelet recovery (defined as reaching a platelet count of Ͼ20 × 10 In practice, the safety of a cell dose is assessed in relation to a threshold dose. 1, 5 We used as threshold the upper 99% confidence interval of the blast count of 13 patients who failed to regenerate rapidly: this gave the figure of 1.3 × 10 6 /kg (dotted line in Figure 6) ; only 2/40 of patients with Ͼ1.3 × 10 6 /kg blasts had delayed platelet recovery. Of a total of 13 patients who had delayed recovery or failure of engraftment, 11 had less than 1.3 × 10 6 /kg blasts ( Figure 6 ). Thus, the predictive value positive was 95% and the specificity 85%. The sensitivity, clinically much less important in this context, was 86%. By comparison, the CFU-GM data available in 27 transplanted patients, with a cut-off point at 4 × 10 4 /kg, show sensitivity of 100%, but specificity of only 67%; the latter was due to two patients with AML who had 21 and 25.8 × 10 4 /kg CFU-GM, but nonetheless experienced delayed platelet recovery. 
Discussion
The demonstration of excellent correlation between morphologically identified blasts in BPC harvests, and the CFU-GM and CD34 + cells, as well as good correlation with the granulocyte and platelet recovery post ABPCT, indicate that blast counts may be used as surrogate markers of haemopoietic progenitor cell content of BPC collections. We are not suggesting that blast counts should replace CD34 or CFU-GM scoring; however, they may be successfully used under circumstances where quick decisions are necessary and no facilities to perform a CD34 cell count are available. In addition, blast counts may be used as an internal quality control test. With regard to assay simplicity, only the mononuclear cell count of the harvest is comparable to blast count, and indeed has been reported to be a good indicator of BPC harvest quality. 7, 8 Although our data broadly agree with these findings, we observed three patients (one with AML, CML, and HD each) with Ͼ4 × 10 8 /kg MNC who either had delayed platelet recovery (87 and 180 days), or had no CFU-GM in the harvests and therefore did not proceed to ABPCT. Increasing the threshold of MNC further results in an unacceptably high proportion of 'falsely negative' values. From the technical point of view, mononuclear cell counts from BPC harvests are not readily obtainable on automated cell counters, and require examination of the film.
In addition to the correlation with CD34/CFU-GM, we found that the threshold of 1.3 × 10 6 /kg blasts defined collections which, when reinfused into the patient, resulted in a rapid haemopoietic recovery. The exception to this rule was two AML patients who experienced prolonged platelet recovery post APBCT (days 50+ and 90), although both had satisfactory blast, CD34 and CFU-GM counts. Delayed platelet regeneration after APBCT for AML, in the presence of cell counts considered to be adequate has been reported, 1, [9] [10] [11] and may indicate abnormalities of haemopoietic stem cells or marrow stroma which impede engraftment. In that respect, blast counts do not seem to be any more informative than CFU-GM or CD34 counts.
A potential problem of uneven distribution of blasts on the film should be overcome by counting 1000 cells. The reproducibility of the morphological identification of blasts was satisfactory, with a median coefficient of variation between three independent observers of 25%. We are certain that this variability can be further reduced, by adopting standard definition of the blast, as in disease classifications based on cell morphology (eg FAB classification). If our results are confirmed by others, they could contribute to better quality control in ABPC transplantation.
